EXEL News and Press, Exelixis Inc. From 09/12/23

— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine’s artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In April 2023, the U.S....

-- Presentations to be webcast on www.exelixis.com -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in September: 2023 Wells Fargo Healthcare C...

2023-08-30 08:00:00 ET Investing in stocks isn't just for the rich and famous since quality stocks can be found at almost any price. Some are trading for well above $1,000 per share, while others go for less than $100 apiece. However, finding stocks under $100 may be better for those who ar...

2023-08-30 07:00:00 ET Summary Exelixis issued two important releases regarding its lead molecule cabozantinib, showing positive results in prostate cancer and advanced pancreatic and extra-pancreatic neuroendocrine tumors. The company's finances and liquidity are solid, with posi...

Shares of Exelixis, Inc. (NASDAQ: EXEL) traded at a new 52-week high today and are currently trading at $22.27. So far today, approximately 432.99k shares have been exchanged, as compared to an average 30-day volume of 2.79M shares. Exelixis, Inc., an oncology-focused biotechnology company, f...

2023-08-24 08:47:07 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis lead product hits main goal in Phase 3 prostate cancer trial Exelixis a new over...

2023-08-24 08:40:38 ET Bruush Oral Care ( BRSH ) +62% . Hitek Global ( HKIT ) +19% . Guess? GES +16% on Q2 earnings release . Groupon ( GRPN ) +14% . Splunk SPLK +14% on Q2 earnings release . Eos Energy Enterprises ( EOSE ) ...

– CABINET trial will be unblinded and stopped early due to a dramatic improvement in efficacy per a unanimous recommendation by The Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board – – Based on positive results, findings will b...

2023-08-24 07:30:00 ET Following the market's gloomy 2022, this year has been a breath of fresh air with the S&P 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. C ystic fibrosis specialist Vertex Pharmaceuticals (NASD...

2023-08-24 03:43:27 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis lead product hits main goal in Phase 3 prostate cancer trial For further details...